Yuxiang Yan

Yuxiang Yan

Auto-generated profile, based on publicly available information

Yuxiang Yan

The Dingli Clinical College of Wenzhou Medical University Wenzhou Zhejiang China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Cell Proliferation
Verified
Journal Article
Open access
XZXiangjian Zhang
Xiangjian Zhang
RZRuiqiu Zhu
Ruiqiu Zhu
DYDie Yu
Die Yu
JWJuan Wang
Juan Wang
YYYuxiang Yan
Yuxiang Yan
KXKe Xu
Ke Xu
Cancer‐associated fibroblasts (CAFs), a phenotypically and functionally heterogeneous stromal cell, are one of the most important components of the tumour microenvironment. Previous studies have consolidated it as a promising target against cancer. However, variable therapeutic efficacy—both protumor and antitumor effects have been observed not least owing to the strong heterogeneity of CAFs. Over the past 10 years, advances in single‐cell RNA sequencing (scRNA‐seq) technologies had a dramatic effect on biomedical research, enabling the analysis of single cell transcriptomes with unprecedented resolution and throughput. Specifically, scRNA‐seq facilitates our understanding of the complexity and heterogeneity of diverse CAF subtypes. In this review, we discuss the up‐to‐date knowledge about CAF heterogeneity with a focus on scRNA‐seq perspective to investigate the emerging strategies for integrating multimodal single‐cell platforms. Furthermore, we summarized the clinical application of scRNA‐seq on CAF research. We believe that the comprehensive understanding of the heterogeneity of CAFs form different visions will generate innovative solutions to cancer therapy and achieve clinical applications.